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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Does
Adalimumab improve symptoms in patients with moderate to severe Hidradenitis Suppurativa?”
STUDY DESIGN: A systematic review of three peer-reviewed articles published between 2011
and 2016 which present patient oriented evidence.
DATA SOURCES: Review incorporated analysis of two randomized controlled trials (RCTs)
and one open label prospective trial. Studies were selected based upon the relevance to the
clinical question, does adalimumab usage improve symptoms in individuals with moderate to
severe hidradenitis suppurativa.
OUTCOMES MEASURED: The outcomes measured focused on patient reported reduction in
hidradenitis suppurativa symptoms. Two studies analyzed outcomes using patient reported
Dermatology Life Quality Index (DLQI) scores, which take into account both physical and
psychological disease burden as reported by the patient. The third study evaluated outcomes by
analyzing the percentage of participants whom reported at least a 30% reduction in pain scores
following adalimumab usage.
RESULTS: The open label trial completed by Sotiriou E, Goussi C, Lallas A, et al. revealed a
significant improvement (P= 0.001) in patient reported DLQI scores following adalimumab
usage for 24 weeks when compared to their initial DLQI scores. The study completed by Miller
I, Lynggaard CD, Lophaven S, et al. failed to show statistically significant improvement in DLQI
scores of patients receiving adalimumab compared to those receiving a placebo. The study by
Kimball AB, Okun MM, Williams DA, et al. revealed inconsistent results concerning patient
reported pain improvement with adalimumab use versus the use of a placebo.
CONCLUSION: Review of the three studies selected revealed inconclusive results. Though the
results were inconsistent between studies, the presence of positive results in two of the studies
indicates that further investigation of the efficacy of adalimumab use for hidradenitis suppurativa
is warranted. Results from the studies analyzed indicate further research should also be carried
out to evaluate the efficacy of simultaneous adalimumab and conventional therapeutic usage.
KEY WORDS: Hidradenitis suppurativa, adalimumab
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Introduction
Hidradenitis suppurativa (HS) is a dermatologic condition characterized by the formation
and recurrence of painful skin nodules, lesions, and sinus tracts that can progress to severe
scarring.1 Patients not only suffer from the visible dermatologic manifestations of HS, but also
the subsequent acute and chronic inflammatory states caused by the presence of these
abnormalities.1 HS patients must grapple with its physical effects as well as its psychological
effects, which are brought about by the chronic pain patients experience alongside feelings of
embarrassment secondary to the visible signs of the disease.2 These combined physical and
psychological sequelae can have a profound effect on the lives of individuals with HS. The fact
that HS greatly affects the quality of patients’ lives and no gold standard therapeutic regimen has
been agreed upon, has led to a multitude of studies evaluating a range of treatment options taking
place with the goal of finding a final solution. This review analyzes three studies that attempted
to determine whether adalimumab is a potential final solution for HS patients.
HS has an incidence of 11.4 per 100,000 people in the United States.3 With its severe
effects, HS must be a differential considered by healthcare providers across primary care fields
as well as dermatologists. HS must also be therapeutically managed by these fields and by
general surgery in more severe cases. Apart from the physical effects, studies have also indicated
that HS patients suffer monetary effects, spending an average of $5,048 on medications annually,
while also incurring greater costs and more frequent visits to the emergency room in comparison
to control groups.4 The latest estimates obtained through analysis of data from 2002 to 2010
indicated that there were about 254,000 health care visits per year addressing HS.5 Overall,
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despite its low prevalence the multispecialty involvement, financial impact, and associated
decreases in quality of life make HS a relevant healthcare topic.
The exact cause of HS has not been agreed upon to this point, but the most well
supported theory is that HS is the result of chronic follicular occlusion of the
folliculopilosebaceous units of the skin.1 The occlusion of these units leads to their distention as
they fill with keratinocytes and potential antigens, and these distended units are thought to be the
foundation and cause of the characteristic skin nodules and lesions associated with HS.1
Subsequent force on the distended units can lead to rupture and dispersal of their contents which
in turn lead to an inflammatory response. This inflammatory response leads to the formation of
sinus tracts and scarring as well as acute and chronic pain.1 HS more commonly effects the
intertriginous areas of the body due to the persistent friction and pressure at these locations.1 This
increased friction and pressure at intertriginous areas causes a greater number of follicular unit
ruptures to occur followed by increased inflammation and scarring compared to other sites.
No “gold standard” therapy has been agreed upon for HS, and this absence of definitive
treatment has fueled the testing and usage of many therapies. One of the first forms of
management used in HS, as with many disease, is lifestyle changes including weight loss and
smoking cessation.6 Data analysis has revealed obese and current smokers are more likely to
develop and experience more severe and progressive HS, so limiting these factors can provide
great benefit.1 The application of antiseptic solutions and antimicrobial lotions at lesion and
nodule sites is an early option, though this approach does not halt the formation or recurrence of
nodules and lesions.6 Initial pharmacologic options including topical antibiotics, such as
clindamycin, oral antibiotics, and retinoids are used to reduce the chances of infection at active
open HS sites and attempt to provide symptom relief.6 Intra-lesional steroid injection is another
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therapeutic measure used to relieve inflammation and attempt to decrease subsequent sinus tract
formation and severe scarring.6 Surgical debridement and excision of active inflammatory
lesions and sinus tracts is a late option considered in uncontrolled HS.1
The above therapies have provided inconsistent results and varying levels of symptom
relief. This inconsistency has led to biologic medications, such as adalimumab, being considered
as a treatment option for HS.6 With the most significant effects of HS being associated with the
immune system’s inflammatory response to follicular rupture,1 therapies which can mediate this
response have become a focus. Adalimumab, a tumor necrosis factor(TNF) alpha inhibitor
medication, is an immunosuppressant.6 Its administration is intended to lead to a less
exaggerated immune and thus inflammatory response to the rupture of the follicular units formed
in HS, and these therapeutic effects are thought to lead to a decrease in sinus tract formation,
chronic inflammation, and severe scarring associated with HS.6
Objective
The objective of this selective evidence based medicine (EBM) review is to determine
whether or not “Does Adalimumab improve symptoms in patients with moderate to severe
Hidradenitis Suppurativa?”
Methods
The three studies used in this systematic review consisted of two double blind
randomized controlled trials and one open label perspective trial. These studies were selected
based upon their relevance to the clinical question posed in this review, and their presentation of
trial results as patient oriented evidence. The population evaluated in each of the three studies
consisted of both men and women over the age of 18 with clinically diagnosed moderate to
severe HS.7,8,9 Two of the studies use the intervention of 40 mg of adalimumab subcutaneously
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weekly,7,9 while the other study had an intervention of 40 mg of adalimumab given
subcutaneously once every two weeks.8 The duration of the studies varied from 12 to 48 weeks.
Comparison within the two randomized controlled trials was done by administering visually
matched placebos to the control group at the same intervals as the groups receiving
adalimumab.8,9 No comparison group was used in the open label perspective trial.7 In all studies
selected, patient reported changes in HS symptoms were the outcomes measured.
The keywords “hidradenitis suppurativa” and “adalimumab” were used in PubMed to
find the studies used within this review. The studies selected were all published in English and
appeared in peer reviewed journals. The inclusion criteria used for the selection of studies
included being peer reviewed, being published after 2010, and presenting outcomes as patient
oriented evidence. Studies presenting non-dichotomous data were analyzed using statistics
including: p-values, z-scores, confidence interval (CI), and mean changes from baseline.7,8
Statistics including number needed to treat (NNT), absolute benefit increase (ABI), and relative
benefit increase (RBI) were used for the analysis of the study containing dichotomous data.9
Table 1 - Demographics & Characteristics of included studies
Study

Type

# Pt

Age(
yrs)

Inclusion Criteria

Exclusion Criteria

W/
D

Interventions

Sotiriou7
(2012)

Prospective
open-label
clinical trial

15

2845

18 years of age or older
with clinically diagnosed
moderate to severe
hidradenitis suppurativa.
HS must have been
present for at least 2
years, and patients have
tried and failed at least 3
systemic treatments.

No treatment with
biologic medications
within in 6 months of the
trial start date. Patients
could not have chronic
or recurrent infection or
chronic systemic
diseases.

0

80 mg of
Adalimumab
given at base
then one 40
mg injectionweekly for 24
weeks.

Miller8
(2011)

Double
Blind,
placebo
controlled
RCT

21

2555

Men and women of at
least 18 years of age with
clinically diagnosed
moderate to severe
hidradenitis suppurativa.
Participants must have

No treatment with
biologic medications
within 6 months or
conventional treatment
within 4 weeks. Patients
could not have chronic

5

80 mg of
Adalimumab
given at base
followed by a
40 mg
injection
every other
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Kimball9
(20112014)

Double
Blind,
placebo
controlled
RCT

633

2448

had hidradenitis
suppurativa for at least 6
months.
18 years or older with
clinically diagnosed
moderate to severe
hidradenitis suppurativa
and an inadequate
response to oral antibiotic
treatment.

or recurrent infection or
chronic systemic
diseases.
Participants could not
have taken oral
antibiotics within 28
days of baseline in trial
1. No other exclusion
criteria were specified.

week for 12
weeks.
37

Adalimumab
40 mg given
every week
for twelve
weeks.

Outcomes Measured
The outcomes evaluated in this review are patient oriented outcomes (POEMs) reported
within the selected studies. These results were reported by the patients in the respective studies
and focused on HS symptom relief brought about by adalimumab usage. The studies by Sotiriou
et al. and Miller et al. reported outcomes using patient reported Dermatology Life Quality
Index(DLQI) scores. DLQI is a scale with a maximum score of 30 that attempts to quantify the
physical pain, impact on daily life, and psychological effects of a dermatological disease
experienced by an individual. Outcomes were based upon comparisons of mean DLQI scores at
baseline with subsequent scores reported by participants throughout the studies. Outcome
evaluation in the study by Kimball et al. consisted of analyzing the percentage of participants
who reported at least a 30% reduction in pain and at least a 1-unit reduction from baseline in the
pain score as rated on a 0 to 10 scale following the usage of adalimumab.
Result
Sotiriou et al. conducted an open-label perspective study done at Aristotle University in
Greece. Of the 20 individuals screened for the study, 15 were selected based upon the inclusion
and exclusion criteria seen in Table 1.7 Qualifying patients were informed of the purpose and
design of the study prior to its start, and all participants underwent the intervention being
evaluated.7

5
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All participants received a subcutaneous dose of 80 mg of adalimumab at baseline,
followed by 40 mg doses given weekly for a 24-week period.7 The DLQI scores of participants
were obtained at baseline, after 24 weeks of adalimumab administration, and after an additional
24-week washout period. The mean DLQI scores of all participants were calculated at these
intervals and were found to be 15.9, 4.8, and 12.2 respectively.7 The change in mean DLQI score
between these intervals was evaluated to determine the effect of adalimumab use. The change
from 15.9 at baseline to 4.8 at the end of the 24-week period of adalimumab usage was found to
be significant (∆= -11.1, P = 0.001, Z = -3.415), indicating a statistically significant
improvement in symptoms with adalimumab use.7 The change in mean DLQI scores from 4.8 at
the end of 24 weeks to 12.2 after the washout period was also found to be significant (∆= 7.4, P=
0.001, Z= -3.423), indicating a significant worsening of symptoms with the cessation of
adalimumab.7 The change from the baseline value of 15.9 to the washout period value of 12.2
was found to be significant (∆= -3.7, P= 0.005, Z= -2.817), indicating prolonged symptom relief
after cessation.7 Based upon the analysis of change in mean DLQI score in this study
adalimumab usage provided a recognizable improvement in HS symptoms, and statistically
significant worsening of symptoms was also seen with the discontinuation of adalimumab. This
analysis is highlighted in Table 2. No major adverse effects were noted throughout the duration
of the study, all participants completed the full therapeutic regimen, and all participants reported
at the end of the washout period.7
Table 2: Change in Mean DLQI scores following administration of adalimumab and
washout period from Sotiriou et al.7
Mean DLQI Score
Change in Mean DLQI
Score from Baseline
Change in Mean DLQI
Score from 24 weeks

Baseline
15.9
-

End of 24 Weeks
4.8
-11.1(P= 0.001, Z= -3.415)

End of 48 Weeks
12.2
-3.7 (P= 0.005, Z= -2.817)

-

-

+ 7.4 (P= 0.001, Z=-3.423)
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Miller et al. conducted a double blind randomized control trial completed at Roskilde
Hospital and Gentofte Hospital in Denmark. 21 patients were selected for the trial based upon the
same inclusion and exclusion criteria as the Sotiriou et al. study, except pregnant women could
also participate in this trial. Computer randomization was used to assign participants to the
experimental and control groups at a 2.5:1 ratio, meaning over twice as many participants
received adalimumab (15) as opposed to those receiving a placebo (6).8
Patients in the experimental group received 80 mg of adalimumab subcutaneously at
baseline followed by 40 mg doses given every other week for twelve weeks. Members of the
control group were given visually matched placebos at these same intervals.8 Participants were
then followed for an additional 12-week washout period for continued evaluation. Changes in
mean DLQI scores were used to measure outcomes in this study, and these values were obtained
at baseline, 12 weeks, and 24 weeks.8 The experimental group mean DLQI scores at these
intervals were 16.07, 12.40, and 16.70 respectively, while the control group scores were 8.33,
9.33, and 9.00 respectively. The changes in mean DLQI score for the experimental group were
-3.67 from baseline to 12 weeks and 0.53 from baseline to the end of the washout period,
compared to changes of 1.00 and 0.67 seen in the control group over these intervals.8 These
scores and differences can be found highlighted in Table 3. Statistical comparison of the changes
in mean DLQI scores experiences by the experiment and control groups were used to determine
the significance of the study results. Comparison of the changes in mean DLQI scores from
baseline to 12 weeks between these two groups revealed a p-value of 0.06, and comparison from
baseline to completion of the washout period revealed a p-value of 0.88. These results revealed
no significant difference based upon the threshold of P ≤ 0.05, and thus the trial failed to show
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an improvement in HS with adalimumab usage versus a placebo. Based on these results it can be
inferred that adalimumab usage did not provide significant symptom relief.
By the conclusion of the study 5 participants had dropped out due to worsening HS
symptoms, 3 from the experimental group and 2 from the control group.8 The study indicates the
main adverse effects experienced by participants were mild infection and nonspecific rash.8 In
the case of individuals who dropped out of the study, the last recorded data point for that
individual was carried forward and used as the reported value at each subsequent interval.
Table 3: Change in Mean DLQI scores from Miller et al.8
Mean DLQI Score

Change in Mean DLQI
Score from Baseline
Significance of Mean
DLQI Change between
Experimental and Control
Groups

Baseline
Experimental Group:
16.07 (CI: 12.13 to 20.00)
Control Group:
8.33 (CI: 4.66 to 12.01)
-

-

End of 12 Weeks
Experimental Group:
12.40 (CI: 7.79 to 17.09)
Control Group:
9.33 (CI: 3.75 to 14.91)
Experimental Group:
-3.67 (CI: -8.99 to 1.66)
Control Group:
1.00 (CI: -1.39 to 3.39)
P = 0.06

End of 24 Weeks
Experimental Group:
16.70 (CI: 12.50 to 20.70)
Control Group:
9.00 (CI: 3.61 to 14.39)
Experimental Group:
0.53 (CI: -4.66 to 5.73)
Control Group:
0.67 (CI: -2.56 to 3.90)
P = 0.88

Kimball et al. completed two large double-blind randomized controlled trials which took
place across 14 different countries at over 200 different sites. Between the two trials a total of
907 people were screened and 633 qualified to participate in the study. The inclusion and
exclusion criteria were again similar to those of the Sotiriou et al. study. Although, in this study
participants were not required to have failed other treatment regimens prior to entering, and in
the second trial patients could continue other antibiotic therapies.9 In both trials the participants
were randomly assigned to the experimental and control groups at a 1:1 ratio.9
The study consisted of several phases in which participants were reassigned to various
groups and given numerous different interventions. For the purposes of consistently, only the
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initial phases of each trial from this study will be evaluated for this systematic review. In both
trials the experimental groups were given weekly doses of 40 mg adalimumab subcutaneously,
while the control groups were given a visually matched placebo weekly.9 Outcomes were
considered positive if, after 12 weeks of adalimumab use, participants reported a 30% or greater
reduction in pain and at least a 1-unit reduction from baseline in pain score as rated on a 0 to 10
scale.9 This evaluation only included individuals who reported pain scores of 3 or higher at the
onset of the study.9 In the initial trial 27.9% of the experimental group reported qualifying pain
reduction compared to 24.8% of the control group (P = 0.63).9 Analysis of this dichotomous data
yields an RBI of 12.5%, an ABI of 3.1%, and an NNT of 33. In the second trial 45.7% of the
experimental group versus 20.7% of the control group reported qualifying pain improvement (P=
0.001).9 This equates to an RBI of 131%, an ABI of 25.9%, and an NNT of 4. The data from the
initial trial indicates that for every 33 individuals treated with adalimumab one additional group
member will recognize a noticeable benefit in comparison to a group of 33 treated with a
placebo, whereas the results from the second trial indicate that an additional benefit would be
seen using groups of only 4 individuals. The results of the second trial indicate adalimumab
usage is much more efficacious than those of the first. For calculation purposes, no value was
entered in the case of participants who withdrew, thus calculations function as if the participants
had never been a part of the trials.9
Table 4: Change in Pain Score from Kimball et al.9
Trial 1
Trial 2

Experimental Group Qualifying Pain
Reduction
27.9% (34/122)
45.7%(48/105)

Control Group Qualifying
Pain Reduction
24.8%(27/109)
20.7%(22/111)

ABI

RBI

NNT

3.1%
25.9%

12.5%
131%

33
4

The study indicated that 17 of the initial 307 participants in the first trial and 20 of 448
participants in the second trial failed to complete the full duration of the phase being evaluated.
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Reasons for the 37 total withdrawals included adverse effects (9), loss to follow up (6), withdraw
of consent (16), and other (6).9 The most common adverse effect noted during the study was
infection.9 In the first trial 28.3% of the experimental group versus 24.8% of the control group
experienced infections, while 25.2% of the experimental group and 32.5% of the control group
experiencing infections in the second trial.9 This data does not appear to show an increased
chance of infection with the usage of adalimumab for a 12-week period compared to usage of a
placebo, though 12 weeks is a short period when considering adverse effect development.
Discussion
Of the three studies evaluated for this review the study by Sotiriou et al. revealed the
most consistent and statistically significant benefits of adalimumab usage, but this trial was also
an open label trial in which the participants were informed of the goals of the study beforehand.7
Prior knowledge that the intervention was being received could have played a role in the positive
results reported by the patients. In the Miller et al. study, the large variance in initial mean DLQI
scores between the experimental and control groups must be considered as a factor with the
potential to effected results.8 Another variable of note is that the largest study, Kimball et al., was
sponsored by a manufacturer of adalimumab.9 The sponsor was involved in the construction of
the study and made aware of all results prior to the publication.9 The manufacturer’s involvement
may have led to a preferential set up towards positive results. This study also yielded inconsistent
results, with the first trial having a NNT of 33 versus a NNT of 4 found in the second trial.9
Though, the second trial obtained more promising results the individuals in this trial could
continue other conventional therapies while also receiving adalimumab. This difference in
parameters between trials can greatly effect results and the ability to attribute positive results
solely to the use of adalimumab.
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Along with efficacy, the financial feasibility and potential adverse effects of a product
must be considered prior to its implementation. A recent study published in 2018 evaluating the
costs of conventional therapies compared to adalimumab for HS treatment revealed an average
yearly cost of € 8,309.60 for conventional therapies versus €3,264.20 for adalimumab.10 This
indicates that adalimumab usage may be the more cost-effective option, but this study was also
partially funded by the adalimumab manufacturer.10 Concerning safety, though the studies in this
review revealed no consistent adverse effects with adalimumab usage, adalimumab is an
immunosuppressant with a black box warning for increased chances of developing serious
infections as well as lymphoma and other malignancies.11 Continued evaluation of the adverse
effects seen with long term adalimumab use must be analyzed to determine whether the potential
benefits outweigh the risks of therapy.
Conclusion
Based upon the above review of three clinical studies it is inconclusive whether
adalimumab improves symptoms in individuals with moderate to severe HS. Only one study
revealed consistent statistically significant improvement of HS symptoms with adalimumab use.7
Of the other two studies, one revealed inconsistent result as discussed above9 and the other failed
to show a significant improvement with the use of adalimumab.8 These inconsistent results may
be attributable to the large differences in study designs, but the presence of positive results in
some trials indicates that further studies should be done concerning the efficacy of adalimumab
use in HS. In future trials, further investigation should be done evaluating whether the use of
adalimumab concomitantly with different conventional therapies is more beneficial than the use
of single agents alone. The results of the second trial in the final study discussed indicate this
may be a more efficacious approach.9
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